Welcome to our dedicated page for Lucid Diagnostics news (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics stock.
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage medical diagnostics company dedicated to cancer prevention, particularly focusing on patients with gastroesophageal reflux disease (GERD). GERD, commonly known as chronic heartburn or acid reflux, places millions at risk of developing esophageal precancer and the highly lethal esophageal adenocarcinoma. Lucid's groundbreaking products, EsoCheck and EsoGuard, are at the forefront of early detection and prevention.
EsoGuard is a bisulfite-converted Next Generation Sequencing (NGS) DNA assay performed on surface esophageal cells collected with the EsoCheck device. This test quantifies methylation at 31 sites on two genes, Vimentin (VIM) and Cyclin A1 (CCNA1), detecting esophageal precancer and cancer with over 90% sensitivity and specificity. EsoCheck is an FDA 510(k) and CE Mark cleared noninvasive swallowable balloon capsule catheter device. This device can sample surface esophageal cells in less than five minutes, providing an effective, non-invasive alternative to costly and invasive endoscopy.
Lucid has shown substantial progress, including solid revenue growth on stable test volumes. Their revenue cycle management processes are improving, and the CYFT program targeting specific groups like firefighters is thriving. Their direct contracting initiative is also accelerating, with near-term prospects for delivering contracts, testing, and revenue.
Recently, Lucid announced a partnership with the Esophageal Cancer Action Network (ECAN) to highlight Esophageal Cancer Awareness Month. Public service videos run on Nasdaq's billboard in Times Square, spreading awareness about the link between heartburn and esophageal cancer.
Lucid's peer-reviewed publication of positive data from a National Cancer Institute (NCI)-sponsored study confirmed the high sensitivity and specificity of the EsoGuard test. This significant milestone supports their goal of widespread screening and early detection, moving towards Medicare coverage.
Lucid continues to advance its operations and strategies, recently closing a $30 million preferred stock financing to support their growth. They are on track to achieve key milestones, including expanded private and public coverage and direct contracting. Lucid's clinical evidence base for EsoGuard is robust, further enhancing their line of sight to Medicare coverage.
For more information, visit www.luciddx.com and their parent company PAVmed at www.pavmed.com.
Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, provided a business update and financial results for the first quarter of 2024. The company reported a 10% increase in EsoGuard test volume, a strengthened balance sheet after a $29.8 million Series B Preferred Stock Offering, and a MolDX pre-submission meeting scheduled for July 17, 2024. Lucid also highlighted revenue growth, clinical study outcomes, and market access strategy.
Lucid Diagnostics Inc. announced that the EsophaCap sponge-on-a-string esophageal cell collection device has been subjected to a Class II FDA recall due to serious device failures reported. Lucid's EsoCheck® remains unaffected by the recall and continues to be the gold standard for non-endoscopic cell collection. The recall stemmed from two serious device failures reported in a recent publication of one of the studies using the EsophaCap device. Lucid's EsoCheck® is a modern technology enabling precise, targeted cell collection for esophageal precancer testing, offering unprecedented early precancer detection without causing any serious adverse events.
Lucid Diagnostics Inc. (Nasdaq: LUCD) has successfully closed a Series B-1 Preferred Stock offering, generating $29.8 million in gross proceeds. The offering was led by a long-time institutional investor, providing the company with substantial working capital. As part of this development, Dennis Matheis, a seasoned healthcare industry veteran, has been appointed to the Board of Directors. Matheis currently holds the position of President and CEO at Sentara Health, a prominent not-for-profit integrated health system in the U.S. Lucid aims to leverage this funding to achieve key reimbursement milestones and enhance its operational capabilities.
Lucid Diagnostics, a cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., will hold a business update conference call and webcast on May 13, 2024, at 8:30 AM ET. The call will feature Lucid's CEO providing an operational overview and growth strategy, along with the CFO discussing first-quarter 2024 financial results. Investors can access the webcast on the company's website or join via telephone.
Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the publication of positive data from a National Cancer Institute-sponsored study on EsoGuard® Esophageal Precancer Testing, showing 89% sensitivity in detecting early precancer. The study strengthens EsoGuard's clinical data and supports efforts for commercial and Medicare coverage.
Lucid Diagnostics, a cancer prevention medical diagnostics company, partners with the Esophageal Cancer Action Network (ECAN) to raise awareness during Esophageal Cancer Awareness Month. The partnership aims to educate about the link between heartburn and esophageal cancer, promoting early detection for prevention. Public service videos are being displayed in Times Square, emphasizing the importance of screening for those at risk.
FAQ
What is the current stock price of Lucid Diagnostics (LUCD)?
What is the market cap of Lucid Diagnostics (LUCD)?
What is Lucid Diagnostics Inc.?
What are EsoCheck and EsoGuard?
Why are GERD patients at risk?
How does EsoGuard work?
What recent achievements has Lucid Diagnostics announced?
What partnerships has Lucid Diagnostics formed?
What are the financial highlights for Lucid Diagnostics?
What is the significance of the NCI-sponsored study?
How does Lucid's technology compare to traditional methods?
What are Lucid's future plans?
